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Summary
Background The incidence, clinical relevance and pathogenesis of single, isolated,
varicella-like skin lesions occurring far beyond the primary herpes zoster (HZ)-
affected dermatome remain unclear.
Objectives To search prospectively for these satellite lesions in 120 patients with HZ and
to correlate their presence with a series of clinical, histological and virological data.
Methods Relevant clinical data were recorded from 109 patients with proven HZ
using immunohistochemistry on Tzanck smears. Furthermore, skin biopsies and
blood samples were obtained from a subgroup of patients presenting with pri-
mary HZ with and without satellite lesions for histology, immunohistology,
serology and real-time polymerase chain reaction.
Results This study identified satellite lesions in 211% of the patients with HZ. Their
presence conveyed a statistically significant relative risk (RR) for severe (RR 327,
P < 0001), multidermatomal (RR 106, P < 0001) and multistage HZ (RR
330, P < 0001); systemic signs (RR 208, P = 00031); immunosuppression (RR
238, P = 00014) and hospitalization (RR 294, P < 0001). Varicella zoster virus
(VZV) viraemia was higher (mean 4075 copies mL1) in patients with HZ with
satellite lesions than in those without (mean 1466 copies mL1). In contrast to HZ
lesions, satellite lesions often presented positive VZV immunostaining in endothe-
lial cells, suggesting a similar pathogenesis to varicella. A limitation of this study is
the centre-linked overrepresentation of immunocompromised patients.
Conclusions Total-body examination searching for satellite lesions is a rapid, simple
and reliable tool for identifying patients with high-risk HZ.
What’s already known about this topic?
• The clinical relevance of varicella zoster virus satellite lesions occurring during her-
pes zoster is unclear.
What does this study add?
• The presence of satellite lesions during herpes zoster conveys a statistically signifi-
cant increased risk for hospitalization of the patient, an immunosuppressive status,
the development of systemic signs, and multistage and multidermatomal herpes
zoster.
• Total-body examination for satellite lesions is a rapid, easy and reliable clinical tool
for identifying patients with high-risk zoster.
The varicella zoster virus (VZV) is responsible for chickenpox and
shingles.1 Occasionally, patients with herpes zoster (HZ) present
simultaneously one or more single, isolated, nonclustered, vari-
cella-like lesions some distance from the primary HZ-afflicted
dermatome.2,3 The incidence, clinical relevance and pathomecha-
nisms of these VZV satellite lesions (SLs) remain unclear.
This study prospectively examined a series of patients with
HZ for the occurrence of SLs and correlated their presence
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with various clinical, histological, immunohistological, sero-
logical and virological features.
Materials and methods
The university hospital ethics committee authorized the study,
and all patients signed an informed consent.
The incidence of SLs among patients with HZ was prospec-
tively studied over a 25-year period (October 2011 to February
2014) in a university medical referral centre. Patients already
taking antiviral therapy were excluded. The clinical diagnosis of
HZ was confirmed by immunohistochemistry using VZV-spe-
cific anti-gE and anti-gB viral envelope antibodies on a Tzanck
smear and/or skin biopsy, following an earlier published proto-
col.4 Antiherpes simplex virus type I and II antibodies were used
to rule out zosteriform herpes simplex infections.4 The included
patients with HZ were specifically screened for SLs, defined as
small, isolated, nonclustered, varicella-like skin lesions occur-
ring at least 5 cm away from the primary HZ dermatome.
Collected clinical data included age, sex, the dermatome
group affected by the primary HZ (cephalic, cervical, thoracic,
lumbar or sacral), the grade of surface of the dermatome(s)
involved by the primary HZ skin lesions [grade 1, isolated
cluster(s) < 10 cm2; grade 2, lesion cluster(s) 10–50 cm2;
grade 3, lesion cluster(s) > 50 cm2], single or multiple adja-
cent dermatomes of the primary HZ, single-stage (papular,
vesicular, pustular or crusted skin lesions) or multistage pri-
mary HZ (simultaneous presence of both papular, vesicular,
pustular and/or crusted cutaneous lesions), prodromal and/or
concomitant pain, systemic signs (fever, malaise, lymphade-
nopathies and/or headache), underlying immunosuppression
and hospitalization for antiviral treatment.
The relative risks (RRs) that SLs provided for any of the
above-mentioned clinical features in a patient with HZ were
calculated, with 95% confidence intervals (CIs) and P-values.
Results were considered to be significant at P < 005. When
considering the RR of 315 and a reference proportion of
012 (nine of 73 with SLs among nonimmunosuppressed sub-
jects), and sample groups of 36 (immunocompromised) and
73 (nonimmunocompromised) patients, with a = 005, the
power is equal to 0835.
To gain insight into the pathogenesis of SLs, the following
materials were sampled from a series of patients with HZ with
an SL at the time of diagnosis: skin biopsies from primary HZ
(n = 15), skin biopsies from an SL (n = 14) and 10-mL ethy-
lenediaminetetraacetic acid (EDTA)–blood samples (n = 14)
for serology and reverse-transcriptase polymerase chain reac-
tion (rt-PCR). For comparison, skin biopsies from primary HZ
(n = 17) and 10-mL EDTA–blood samples (n = 20) were col-
lected from patients with HZ without SLs at the time of diag-
nosis. Cutaneous biopsies were available from four of the
eight patients with varicella.
Histology was used to assess epidermal and/or infundibular
cytopathic effects with giant-cell formation and/or intranucle-
ar inclusions, eventual perivascular lymphohistiocytic infiltrates
and signs of vasculitis.
Immunohistology was performed on skin biopsies using
anti-gE and anti-gB antibodies following an earlier published
protocol.4 VZV serology was evaluated using a VZV-specific
IgG and IgM enzyme-linked immunosorbent assay (ELISA).
VZV viraemia was assessed and quantified by VZV–open read-
ing frame 21-based rt-PCR according to a previously reported
protocol.5 For the immunohistochemical, ELISA and rt-PCR
assays, patients with varicella (n = 8), patients with orolabial
herpes (n = 4) and healthy subjects (n = 6) were included as
controls.
Results
In total, 120 patients had a clinical suspicion of HZ, which
was confirmed by immunohistochemical screening in 109.
Thirty-six patients were immunocompromised. Among those
with HZ with SLs this was due to: haemopathies (n = 6)
(three chronic lymphocytic leukaemia, one acute lymphocytic
leukaemia, one acute myeloid leukaemia and one myelodys-
plastic syndrome); solid organ transplant (n = 2 renal and 1
cardiac); bone marrow transplant (n = 2); HIV (n = 1); and
chemotherapy for breast cancer (n = 2). Among those with
HZ without SLs this was due to: haemopathies (n = 3) (two
chronic lymphocytic leukaemia and one acute myeloid leukae-
mia); solid organ transplant (n = 3 renal); bone marrow
transplant (n = 5); HIV (n = 1); metastatic prostate cancer
(n = 2); chemotherapy for small cell lung cancer (n = 1),
breast cancer (n = 3) or metastatic melanoma (n = 1); tumour
necrosis factor (TNF) antagonists for rheumatoid arthritis
(n = 2) and TNF antagonists combined with oral corticoster-
oids for hidradenitis suppurativa (n = 1).
SLs were observed in 23 of 109 (211%) of the patients.
Among the patients with HZ with SLs, nine were immunocom-
petent (mean age 693 years, range 28–88, median 77) and 14
were immunocompromised (mean age 599 years, range 22–
82, median 615). Of all the included immunocompromised
patients with HZ, 39% presented SLs (mean age 611 years,
range 22–91, median 615), vs. 12% of the 73 immunocompe-
tent patients (mean age 639 years, range 24–84, median 68).
Hence, immunocompromised patients with HZ presented a
315-fold increased RR of exhibiting SLs compared with immu-
nocompetent patients (95% CI 151–659, P = 00014).
The number of SLs ranged from five to 40. Immunocom-
promised patients with HZ presented significantly more SLs
(mean 273, range 10–40) than immunocompetent patients
with HZ (mean 117, range 5–21). The lesions presented as
clear or pustular vesicles with a central depression, sometimes
crusted and/or ulcerated, and were occasionally slightly haem-
orrhagic (Fig. 1). The most frequent localization of SLs was
the trunk (20 of 23), with others on the head and neck area
(one of 23) and the extremities (two of 23). The SLs were
not pruritic or painful. The other clinical results for patients
with and without SLs are presented in Table 1. The patients
received an antiviral treatment: oral aciclovir, oral valaciclovir
or intravenous aciclovir. No case of motor paresis or systemic
or lethal disseminated VZV disease was recorded.
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The statistically significant RRs for the presence of SLs con-
veyed in a given patient with HZ are as follows. Systemic signs,
RR 208 (95% CI 135–330, P = 00031); immunosuppres-
sion, RR 238 (95% CI 146–387, P = 00014); multistage HZ,
RR 330 (95% CI 196–555, P < 0001); multidermatomal
HZ, RR 106 (95% CI 472–238, P < 0001); HZ surface
involvement grade 3, RR 327 (95% CI 189–567, P < 0001)
and hospitalization, RR 294 (95% CI 155–558, P < 0001).
The histological alterations of the epidermis were similar
between HZ, SLs, varicella and herpes simplex (Fig. 2a,b and
Table 2). Immunohistology demonstrated an epidermal VZV
gE and gB distribution pattern that was indistinguishable
between HZ lesions, SLs and varicella skin lesions (Fig. 2c,d)
(Table 2).
A variably dense lymphohistiocytic perivascular dermal infil-
trate was present in nearly all of the cases of HZ with and
without SLs. In contrast, SLs showed a higher number of vas-
culitic changes than the HZ lesions (Table 2). The skin lesions
from the primary HZ site from patients with and without SLs
showed positive VZV immunostaining in the dermal dendro-
cytes of the upper reticular dermis, but not in the perivascular
dermal dendrocytes and endothelial cells (Fig. 2c) (Table 2).
Positive VZV immunostaining of endothelial cells and perivas-
cular dermal dendrocytes was seen in all cases of varicella, in
more than half of the cases with SLs (Fig. 2d) and in only
one case of HZ (Table 2).
All patients with HZ with and without SLs showed positive
VZV-specific IgG and negative IgM levels, indicating a status
of past varicella infection and ruling out cases of primary con-
tact with VZV.
The mean viral copy number was lower in the patients with
HZ without SLs compared with those with SLs: 1466 copies
mL1 (range 49–7192) vs. 4075 copies mL1 (range 40–
23 139), respectively. Immunocompromised patients with HZ
with SLs also presented a higher mean number of viral copies
than immunocompetent patients (6970 vs. 730 copies mL1,
respectively). Patients with varicella presented a high-load VZV





Fig 1. (a) Primary herpes zoster (HZ) of the
T5,6 dermatomes and (b) high-power
magnification of the satellite lesions. (c)
Primary HZ of the T7,8 dermatomes. (d)
Primary HZ of the T1 dermatome. Black
arrows, primary HZ; yellow arrows, satellite
lesions.
Table 1 Clinical features of patients with herpes zoster (HZ) with and
without satellite lesions
HZ without satellite
lesions, n = 86
HZ with satellite
lesions, n = 23
Mean age (years) 579 609
Sex (male/female) 41/45 11/12
Dermatome
Cephalic 22 (26) 9 (39)
Cervical 10 (12) 3 (13)
Thoracic 45 (52) 7 (30)
Lumbar 7 (8) 4 (17)
Sacral 2 (2) 0
HZ surface involvementa
Grade 1 25 (29) 2 (9)
Grade 2 35 (41) 7 (30)
Grade 3 16 (19) 14 (60)
Dermatomes
Single 80 (93) 7 (30)
Multiple 6 (7) 16 (70)
NZ stages
Single stage 69 (80) 7 (30)
Multistage 17 (20) 16 (70)
Prodromal and
concomitant pains
53 (62) 15 (65)
Systemic signsb 27 (31) 13 (57)




14 (16) 10 (43)
Values are n (%). aHZ surface involvement grades: grade 1, lesion
clusters < 10 cm2; grade 2, clusters 10–50 cm2; grade 3, clusters
> 50 cm2. bFever, lymphadenopathies, malaise and/or headache.
© 2014 British Association of DermatologistsBritish Journal of Dermatology (2015) 172, pp1530–1534
1532 Zoster satellite lesions, L. el Hayderi et al.
All positive and negative controls were consistently positive
and negative.
Discussion
This study revealed that SLs occurred 315 times more fre-
quently in immunocompromised patients with HZ than in
immunocompetent patients. About 21% of all included
patients with HZ presented one or more SL. This percentage
may be overestimated due to the tertiary-care setting, which
probably receives the more severe cases of HZ. This study also
demonstrated that SLs in a given patient with HZ increase the
RR for developing systemic signs, multidermatomal HZ, mul-
tistage HZ and extensive cutaneous involvement, and for hos-
pitalization and immunosuppression, all representing typical
clinical predictors for severe HZ that could potentially progress
to organ- and life-threatening dissemination. In summary, SLs
in a patient with HZ emerge as a novel clinical predictor of
high-risk HZ disease.
SLs might be mistaken for disseminated cutaneous lesions
of primary HZ. However, several arguments support that SLs
originate through vascular dissemination of VZV particles and
are hence not related to the neural pathway of HZ. Firstly,
there is the striking clinical similarity between SLs and vari-
cella lesions. Secondly, no clustered SLs or SLs in a dermato-
mal pattern were observed, contrasting with HZ. Finally,
Table 2 Results of histology and immunohistochemistry
HZ without satellite lesions HZ with satellite lesions Varicella
Histology
HZ skin lesions Epidermal cytopathic effects 17/17 (100) 15/15 (100) 4/4 (100)
Perivascular
lymphohistiocytic infiltrate
15/17 (88) 14/15 (93) 4/4 (100)
Signs of vasculitis 1/17 (6) 0/15 (0) 3/4 (75)




Signs of vasculitis 6/14 (42)
Immunohistochemistry (positive gE and gB signal)
HZ skin lesions Epidermal and/or
infundibular keratinocytes
17/17 (100) 15/15 (100) 4/4 (100)
Perivascular dermal dendritic cells 1/17 (58) 1/15 (66) 4/4 (100)
Endothelial cells 1/17 (58) 1/15 (66) 4/4 (100)
Satellite lesions Epidermal and/or infundibular keratinocytes NA 14/14 (100) NA
Perivascular dermal dendritic cells 8/14 (57)
Endothelial cells 8/14 (57)
Values are n/N (%). HZ, herpes zoster; NA, not applicable.
(a) (b)
(c) (d)
Fig 2. (a) Epidermal cytopathic effects during
herpes zoster (HZ). (b) Epidermal cytopathic
effects in a satellite lesion. (c) Epidermal
(black arrow) and dermal dendrocyte (red
arrow) varicella zoster virus (VZV)
immunostaining in the reticular dermis of an
HZ skin lesion. Absence of VZV
immunostaining in the small vessels (blue
arrow). (d) Epidermal VZV immunostaining
of the epidermis (black arrow), dermal
dendrocytes (red arrow) and in the superficial
vascular plexus (yellow arrows).
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histology revealed vasculitic alterations in three of four vari-
cella lesions and in 42% of the 14 SLs, but in only one of 32
cases of HZ. In addition, immunohistochemistry demonstrated
VZV gE and gB in endothelial cells and perivascular dermal
dendritic cells in 57% of the SLs. These data suggest VZV vira-
emia in patients with HZ with SL. Indeed, in 57% of the
patients with SLs, a VZV viraemia was measured, with a mean
viral load of 4075 copies mL1. The patients with HZ not
exhibiting SLs presented a viraemia in only 50% of cases, and
the viral load was significantly lower (1466 copies mL1). In
contrast, all patients with varicella presented a significant viral
load (30 431 copies mL1).
Previous studies demonstrated transitory VZV viraemia with a
low viral load in some immunocompetent patients with acute
HZ, and the presence of VZV DNA in all of the immunocompro-
mised patients.6,7 The viral load clearly correlated with the
severity of VZV disease.8–14 Even if the literature is not always
consistent, due to a wide variability of PCR techniques and sam-
pling time points, most studies7–11 suggest that a higher VZV
viral load is associated with more severe immunosuppression
and/or HZ severity. This is in accordance with our results.
In conclusion, total-body examination searching for SLs in a
patient with HZ is a novel, rapid, simple, efficient and reliable
clinical tool for identifying patients with high-risk HZ. SLs
probably share the same pathogenic mechanisms as varicella
skin lesions.
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